Announced details
Treatment of skin defects, burns and other conditions
The epithelialization rate on day 7 after the first application of the product was favorable and exceeded the efficacy of existing treatments
Recipient of the application for marketing approval
No impact on the full-year earnings forecast for the fiscal year ending March 2026
The company does not address Contract Value / Offering price.
Company research (description as the world's first, as of the announcement date)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Allo-JaCE03 (Allo-JaCE Zero Three) |
| Counterparty | Ministry of Health, Labour and Welfare |
| Relationship with the Company | Recipient of the application for marketing approval |
| Applicable area | Treatment of skin defects, burns and other conditions |
| Quantitative Effects | The epithelialization rate on day 7 after the first application of the product was favorable and exceeded the efficacy of existing treatments |
| Impact on Business Performance | No impact on the full-year earnings forecast for the fiscal year ending March 2026 |
| Source | Company research (description as the world's first, as of the announcement date) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Products made using the patient's own cells require a culture period before they can be provided, making it difficult to adequately meet urgent treatment needs.